[go: up one dir, main page]

CA2370553A1 - Traitement cardiovasculaire et osseux au moyen d'isoflavones - Google Patents

Traitement cardiovasculaire et osseux au moyen d'isoflavones Download PDF

Info

Publication number
CA2370553A1
CA2370553A1 CA002370553A CA2370553A CA2370553A1 CA 2370553 A1 CA2370553 A1 CA 2370553A1 CA 002370553 A CA002370553 A CA 002370553A CA 2370553 A CA2370553 A CA 2370553A CA 2370553 A1 CA2370553 A1 CA 2370553A1
Authority
CA
Canada
Prior art keywords
formononetin
isoflavones
treatment
bone
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370553A
Other languages
English (en)
Inventor
Graham Edmund Kelly
Alan James Husband
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kazia Research Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370553A1 publication Critical patent/CA2370553A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne des compositions contenant de la formononétine et/ou une ou plusieurs isoflavones choisies dans le groupe constitué par biochanine, génistéine et daïdzéine, dans un rapport thérapeutiquement efficace de la formononétine aux isoflavones variant entre 15:1 et 2:1, éventuellement associées à un ou plusieurs supports, excipients et/ou diluants. L'invention concerne également des méthodes de traitement comprenant ces compositions, telles que la prévention et/ou le traitement d'une maladie cardiovasculaire, l'altération bénéfique des taux de lipoprotéines dans le sang, la réduction du risque d'affection vasculaire, de coronaropathie ou d'artériosclérose, l'altération bénéfique ou l'entretien de la densité osseuse, notamment dans la prévention ou le traitement de l'ostéoporose, et/ou la prévention et/ou le traitement d'une fracture osseuse.
CA002370553A 1999-04-28 2000-04-27 Traitement cardiovasculaire et osseux au moyen d'isoflavones Abandoned CA2370553A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ0083 1999-04-28
AUPQ0083A AUPQ008399A0 (en) 1999-04-28 1999-04-28 Cariovascular applications
PCT/AU2000/000384 WO2000064438A1 (fr) 1999-04-28 2000-04-27 Traitement cardiovasculaire et osseux au moyen d'isoflavones

Publications (1)

Publication Number Publication Date
CA2370553A1 true CA2370553A1 (fr) 2000-11-02

Family

ID=3814286

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370553A Abandoned CA2370553A1 (fr) 1999-04-28 2000-04-27 Traitement cardiovasculaire et osseux au moyen d'isoflavones

Country Status (7)

Country Link
EP (1) EP1173165A4 (fr)
JP (1) JP2002542286A (fr)
AU (1) AUPQ008399A0 (fr)
CA (1) CA2370553A1 (fr)
HK (1) HK1043546A1 (fr)
NZ (1) NZ513328A (fr)
WO (1) WO2000064438A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7993684B2 (en) 2003-09-19 2011-08-09 Sunstar Inc. Method of inhibiting alveolar bone resorption and periodontal membrane loss and composition for internal use to be used therein

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830887A (en) 1992-05-19 1998-11-03 Novogen Research Pty. Ltd. Health supplements containing phyto-oestrogens, analogues or metabolites thereof
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPQ008299A0 (en) 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
AU2008200518B2 (en) * 2001-03-16 2010-04-01 Novogen Research Pty Ltd Treatment of restenosis
JP4256679B2 (ja) * 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法
JP5060691B2 (ja) * 2001-07-09 2012-10-31 雪印メグミルク株式会社 栄養組成物
DE10151363A1 (de) * 2001-10-17 2003-05-08 Schering Ag Somatotrope Therapie
EP1325681A1 (fr) * 2001-12-11 2003-07-09 Société des Produits Nestlé S.A. Composition pour la promotion de la croissance osseuse et la conservation de la santé osseuse
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
US20090221690A1 (en) 2006-02-28 2009-09-03 Council Of Scientific And Industrial Research Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof
BRPI0708361A2 (pt) 2006-02-28 2011-05-24 Nestec Sa composições e métodos para a indução de crescimento ósseo e para a inibição de perda óssea
US20080108696A1 (en) 2006-08-02 2008-05-08 Brinton Roberta D Phytoestrogenic Formulations for Alleviation or Prevention of Neurodegenerative Diseases
JP2009545605A (ja) * 2006-08-02 2009-12-24 ユニバーシティ オブ サザン カリフォルニア フィトエストロゲン製剤およびその使用
US8680140B2 (en) 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
JP5517613B2 (ja) * 2007-05-28 2014-06-11 不二製油株式会社 エクオール非産生者用の血中エクオール産生促進組成物
WO2013050930A1 (fr) * 2011-10-02 2013-04-11 Sinoveda Canada, Inc, Développement d'un produit de phytoestrogène de trèfle des prés pour la prévention ou le traitement de l'ostéoporose
US9333192B2 (en) 2010-02-15 2016-05-10 Sinoveda Canada, Inc Phytoestrogen product of red clover and pharmaceutical uses thereof
RU2552300C2 (ru) * 2013-10-23 2015-06-10 Государственное бюджетное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Минздрава Российской Федерации Способ коррекции состояния костной ткани и профилактики возникновения переломов у больных с сердечно-сосудистыми заболеваниями
JP6781427B2 (ja) * 2016-05-24 2020-11-04 学校法人日本大学 ダイゼインを有効成分として含む歯の後戻り抑制剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830887A (en) * 1992-05-19 1998-11-03 Novogen Research Pty. Ltd. Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
JPH10114653A (ja) * 1996-10-11 1998-05-06 Taishi Shokuhin Kogyo Kk 骨形成促進および骨塩量減少防止用組成物
DE19650777A1 (de) * 1996-12-06 1998-06-10 Meto International Gmbh Verfahren und Vorrichtung zur Herstellung von deaktivierbaren Sicherungselementen
US6340703B1 (en) * 1997-05-01 2002-01-22 Novogen, Inc. Treatment or prevention of osteoporosis
AUPP260798A0 (en) * 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7993684B2 (en) 2003-09-19 2011-08-09 Sunstar Inc. Method of inhibiting alveolar bone resorption and periodontal membrane loss and composition for internal use to be used therein

Also Published As

Publication number Publication date
AUPQ008399A0 (en) 1999-05-27
NZ513328A (en) 2004-01-30
WO2000064438A1 (fr) 2000-11-02
HK1043546A1 (zh) 2002-09-20
JP2002542286A (ja) 2002-12-10
EP1173165A1 (fr) 2002-01-23
EP1173165A4 (fr) 2004-05-12

Similar Documents

Publication Publication Date Title
CA2370553A1 (fr) Traitement cardiovasculaire et osseux au moyen d'isoflavones
US20040072765A1 (en) Cardiovascular and bone treatment using isoflavones
RU2205015C2 (ru) Композиция на основе стерина (варианты) и способ снижения концентрации общего холестерина и холестерина липопротеина низкой плотности в крови людей (варианты)
CA2287965C (fr) Traitement ou prevention des symptomes menopausiques et de l'osteoporose
AU2002227771B2 (en) Regulation of lipids and/or bone density and compositions therefor
Bolla Soybean consumption and health benefits
JPH11139973A (ja) 血中のｌｄｌ−コレステロール濃度を減少しｈｄｌ−コレステロール濃度を増加させ、アテローム硬化症及び道管病の危険性を減少させる方法
EP0971695A1 (fr) Isoflavonoides destines a traiter et a prevenir la demence de type alzheimer et la reduction des facultes cognitives
JP2002530347A (ja) 大豆蛋白質、食物繊維およびフィトエストロゲン化合物を含む組成物、および心臓血管疾患の予防および／または治療におけるその使用
ZA200400783B (en) Composition for lowering blood cholesterol
JP2003524610A (ja) 大豆蛋白質、食物繊維およびフィトエストロゲン化合物を含む組成物、および２型糖尿病、代謝症候群および関連する心臓血管疾患の予防および／または治療におけるその使用
AU2002227771A1 (en) Regulation of lipids and/or bone density and compositions therefor
CA2325631A1 (fr) Therapie destinee aux troubles lies aux oestrogenes
AU5316899A (en) Soy formulations and their use for promoting health
US6326366B1 (en) Hormone replacement therapy
KR102519649B1 (ko) 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
EP1082122A1 (fr) Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine
AU761047B2 (en) Cardiovascular and bone treatment using isoflavones
KR101502465B1 (ko) 고량강 추출물을 포함하는 골 관련 질환 또는 혈관 석회화의 예방 또는 치료용 약학적 조성물
DK174072B1 (da) Farmaceutisk formulering samt anvendelse heraf til fremstilling af et middel til behandling af kredsløbssygdomme.
JP2004155780A (ja) 生活習慣病改善剤組成物
JP2006022082A (ja) 脂質代謝改善剤
KR20200038411A (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학 조성물
US6998397B2 (en) Method for decreasing cholesterol level in blood
AU783820B2 (en) Composition for and method of reducing low density lipoprotein cholesterol concentration

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued